158 related articles for article (PubMed ID: 7553685)
61. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.
Eisen T; Hedlund G; Forsberg G; Hawkins R
Curr Oncol Rep; 2014 Feb; 16(2):370. PubMed ID: 24445502
[TBL] [Abstract][Full Text] [Related]
62. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.
Wahlsten JL; Mills CD; Ramakrishnan S
J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706
[TBL] [Abstract][Full Text] [Related]
63. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
64. A superantigen bioassay to detect staphylococcal enterotoxin A.
Hawryluk T; Hirshfield I
J Food Prot; 2002 Jul; 65(7):1183-7. PubMed ID: 12117256
[TBL] [Abstract][Full Text] [Related]
65. Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model.
Reddy PN; Paul S; Sripathy MH; Batra HV
Toxicon; 2015 Sep; 103():106-13. PubMed ID: 26091873
[TBL] [Abstract][Full Text] [Related]
66. Functional activity of staphylococcal enterotoxin A requires interactions with both the alpha and beta chains of HLA-DR.
Dowd JE; Karr RW; Karp DR
Mol Immunol; 1996 Nov; 33(16):1267-74. PubMed ID: 9129163
[TBL] [Abstract][Full Text] [Related]
67. Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.
Lando PA; Dohlsten M; Hedlund G; Brodin T; Sansom D; Kalland T
Immunology; 1993 Oct; 80(2):236-41. PubMed ID: 7505257
[TBL] [Abstract][Full Text] [Related]
68. Enhancement of specific immunoglobulin production in SCID-hu-PBL mice after in vitro priming of human B cells with superantigen.
Mårtensson C; Ifversen P; Borrebaeck CA; Carlsson R
Immunology; 1995 Oct; 86(2):224-30. PubMed ID: 7490122
[TBL] [Abstract][Full Text] [Related]
69. Superantigens: interaction of staphylococcal enterotoxins with MHC class II molecules.
Rich RR; Mollick JA; Cook RG
Trans Am Clin Climatol Assoc; 1990; 101():195-204; discussion 204-6. PubMed ID: 2577245
[TBL] [Abstract][Full Text] [Related]
70. Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells.
Hansson J; Ericsson PO; Dohlsten M; Sjögren HO; Kalland T; Hedlund G
Immunol Lett; 1992 Dec; 34(3):229-36. PubMed ID: 1487309
[TBL] [Abstract][Full Text] [Related]
71. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity.
Newton DW; Dohlsten M; Olsson C; Segrén S; Lundin KE; Lando PA; Kalland T; Kotb M
J Immunol; 1996 Nov; 157(9):3988-94. PubMed ID: 8892632
[TBL] [Abstract][Full Text] [Related]
72. Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein.
Sun J; Zhao L; Teng L; Lin F; Zhang H; Li Z; Gao Q
PLoS One; 2011 Feb; 6(2):e16642. PubMed ID: 21311755
[TBL] [Abstract][Full Text] [Related]
73. Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy.
Bashraheel SS; Goda SK
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445686
[TBL] [Abstract][Full Text] [Related]
74. Construction and characterization of a novel superantigen fusion protein: bFGF/SEB.
Wang L; Zhang H; Zhang S; Yu M; Yang X
Cancer Invest; 2009 May; 27(4):376-83. PubMed ID: 19160106
[TBL] [Abstract][Full Text] [Related]
75. Cytokine induction by Mycoplasma arthritidis-derived superantigen (MAS), but not by TSST-1 or SEC-3, is correlated to certain HLA-DR types.
Alvarez-Ossorio L; Johannsen M; Alvarez-Ossorio R; Nicklas W; Kirchner H; Rink L
Scand J Immunol; 1998 Jan; 47(1):43-7. PubMed ID: 9467657
[TBL] [Abstract][Full Text] [Related]
76. Superantigens anergize cytokine production but not cytotoxicity in vivo.
Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T
Immunology; 1994 May; 82(1):117-25. PubMed ID: 7913912
[TBL] [Abstract][Full Text] [Related]
77. Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by a monoclonal antibody to toxic shock syndrome toxin-1.
Kum WW; Chow AW
J Infect Dis; 2001 Jun; 183(12):1739-48. PubMed ID: 11372026
[TBL] [Abstract][Full Text] [Related]
78. Receptors for toxic shock syndrome toxin-1 and staphylococcal enterotoxin A on human blood monocytes.
See RH; Krystal G; Chow AW
Can J Microbiol; 1992 Sep; 38(9):937-44. PubMed ID: 1281444
[TBL] [Abstract][Full Text] [Related]
79. Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Ichiyama M; Tsumoto K; Asano R; Kumagai I; Imai K; Hinoda Y; Matsuno S; Kudo T
Cancer Immunol Immunother; 2001 Dec; 50(10):539-48. PubMed ID: 11776376
[TBL] [Abstract][Full Text] [Related]
80. Superantigens subvert the neutrophil response to promote abscess formation and enhance Staphylococcus aureus survival in vivo.
Xu SX; Gilmore KJ; Szabo PA; Zeppa JJ; Baroja ML; Haeryfar SM; McCormick JK
Infect Immun; 2014 Sep; 82(9):3588-98. PubMed ID: 24914221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
